CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Acorda Therapeutics Inc. v. Mylan Pharmaceuticals Inc.

1:14-cv-00935

Overview

Case Number 1:14-cv-00935
Filing Date 2014-07-16
Status Terminated
Termination Date 2017-04-25
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement

Parties

Defendant

Mylan Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Mylan Pharmaceuticals Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Plaintiff

Alkermes Pharma Ireland Limited NPE (University / Research)

Represented By

0 Attorneys Listed
No attorneys available

Acorda Therapeutics Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 4 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 5 proceedings
πŸ›οΈ
USPTO PTAB Trials 6 proceedings
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (4): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (11 found):
PTAB: 6 U.S. Courts: 5
USPTO PTAB Trial 2015-09-03
IPR2015-01858

Coalition for Affordable Drugs (ADROCA) LLC v. Acorda Therapeutics, Inc.

Asserted Patent
Status: Final Written Decision
USPTO PTAB Trial 2015-09-03
IPR2015-01857

Coalition For Affordable Drugs (ADROCA) LLC v. Acorda Therapeutics, Inc.

U.S. Continuation Sibling (8663685)
Status: Final Written Decision
USPTO PTAB Trial 2015-09-02
IPR2015-01853

Coalition For Affordable Drugs (ADROCA) LLC v. Acorda Therapeutics, Inc.

U.S. Continuation Sibling (8007826)
Status: Final Written Decision
USPTO PTAB Trial 2015-09-02
IPR2015-01850

Coalition For Affordable Drugs (ADROCA) LLC v. Acorda Therapeutics, Inc.

U.S. Continuation Sibling (8440703)
Status: Final Written Decision
USPTO PTAB Trial 2015-02-27
IPR2015-00817

Coalition for Affordable Drugs (ADROCA) LLC v. Acorda Therapeutics, Inc.

U.S. Continuation Sibling (8007826)
Status: Institution Denied
USPTO PTAB Trial 2015-02-10
IPR2015-00720

Coalition for Affordable Drugs (ADROCA) LLC v. Acorda Therapeutics, Inc.

U.S. Continuation Sibling (8663685)
Status: Institution Denied
U.S. District Court 2015-09-15
1:15-cv-00824

Acorda Therapeutics Inc. v. Par Pharmaceutical Inc.

Asserted Patent
Status: DED
U.S. District Court 2015-05-15
1:15-cv-00391

Acorda Therapeutics Inc. v. Sun Pharmaceutical Industries Limited

Asserted Patent
Status: DED
U.S. District Court 2014-07-18
1:14-cv-00955

Acorda Therapeutics Inc. v. Apotex Corp.

Asserted Patent
Status: DED
U.S. District Court 2014-07-15
1:14-cv-00932

Acorda Therapeutics Inc. v. Accord Healthcare Inc.

Asserted Patent
Status: DED
U.S. District Court 2014-07-11
1:14-cv-00917

Acorda Therapeutics Inc. v. Alkem Laboratories Ltd.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

5 Patents

There are 5 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US5540938
Formulations and their use in the treatment of neurological diseases
Filed: 1994-10-24
Issued: 1996-07-30
Expired (Term Ended) +1375d PTA
Expires: 2018-07-30
US8007826
Sustained release aminopyridine composition
Filed: 2004-12-13
Issued: 2011-08-30
Active (0.5 yrs remaining) +894d PTA
Expires: 2027-05-26
US8354437
Method of using sustained release aminopyridine compositions
Filed: 2005-04-08
Issued: 2013-01-15
Active (1.4 yrs remaining) +1119d PTA
Expires: 2028-05-01
US8440703
Methods of using sustained release aminopyridine compositions
Filed: 2011-11-18
Issued: 2013-05-14
Active (5.0 yrs remaining)
Expires: 2031-11-18
US8663685
Sustained release aminopyridine composition
Filed: 2011-07-20
Issued: 2014-03-04
Expired (Term Ended)
Expires: 2025-02-26

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+1375 days) / In re Cellect scrutiny applies.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Docket Entries

(3 total)
Pleading / Complaint

SUMMONS Returned Executed by Alkermes Pharma Ireland Limited, Acorda Therapeutics Inc.. Mylan Pharmaceuticals Inc. served on 7/16/2014, answer due 8/6/2014. (Noreika, Maryellen) (Entered: 07/17/2014)

Entry #6 • 2014-07-17
PACER Document
Pleading / Complaint

ANSWER to 1 Complaint, -- Mylan Pharmaceuticals Inc.'s Answer, Defenses, and Counterclaims to the Complaint for Patent Infringement --, COUNTERCLAIM against Acorda Therapeutics Inc., Alkermes Pharma Ireland Limited by Mylan Pharmaceuticals Inc..(Matterer, Mary) (Entered: 02/20/2015)

Entry #43 • 2015-02-20
PACER Document
Court Order

PROPOSED ORDER -- Scheduling Order -- re (25 in 1:14-cv-00932-LPS, 23 in 1:14-cv-00917-LPS, 22 in 1:14-cv-00922-LPS, 23 in 1:14-cv-00909-LPS, 53 in 1:14-cv-00935-LPS, 15 in 1:15-cv-00077-LPS, 22 in 1:14-cv-00941-LPS, 27 in 1:14-cv-00882-LPS, 23 in 1:14-cv-00955-LPS) Oral Order,,, by Acorda Therapeutics Inc., Alkermes Pharma Ireland Limited. (Tigan, Jeremy) (Entered: 04/17/2015)

Entry #54 • 2015-04-17
PACER Document

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc